EVENT FREE SURVIVAL AT 12 MONTHS AND 24 MONTHS AS PREDICTORS FOR OUTCOME OF SYSTEMIC PERIPHERAL T CELL LYMPHOMA: ANALYSIS OF NATIONWIDE THAI LYMPHOMA STUDY GROUP
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.88_2630
Abstract: ysis of Tfh markers, many kinds of Tfh markers in PTCL with Tfhphenotype are less observed than AITL and more than PTCL, NOS. Among clinicopathological features of PTCL with Tfh-phenotype, cases with PS≥2 (P =… read more here.
Keywords: lymphoma; months predictors; months months; survival months ... See more keywords
Everolimus in Pancreatic Neuroendocrine Carcinomas G3
Sign Up to like & getrecommendations! Published in 2017 at "Pancreas"
DOI: 10.1097/mpa.0000000000000762
Abstract: Objective The aim of this study was to investigate everolimus efficacy in well-moderately differentiated pancreatic NEC (pNEC) G3. Methods This was a retrospective analysis of patients with pNEC G3 and Ki67 20% to 55% treated… read more here.
Keywords: neuroendocrine carcinomas; pancreatic neuroendocrine; survival months; oncology ... See more keywords
The Management and Prognosis of Facial and Scalp Angiosarcoma: A Retrospective Analysis of 15 Patients.
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Plastic Surgery"
DOI: 10.1097/sap.0000000000001865
Abstract: BACKGROUND Angiosarcomas are extremely aggressive malignant tumors that arise from vascular endothelial cells. The risk factors, etiology, prognostic factors, and optimal management strategies for angiosarcomas are as yet unknown. METHODS We retrospectively analyzed data from… read more here.
Keywords: management; recurrence; survival months; months respectively ... See more keywords
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021006889
Abstract: Key Points RUX dose, spleen response, and transfusion requirement in the first 6 months of RUX treatment predict overall survival in MF. The RR6 model overcomes conventional risk stratification in RUX-treated MF. read more here.
Keywords: predict; predict survival; model predict; model ... See more keywords
Prognostic factors following resection of intracranial metastases
Sign Up to like & getrecommendations! Published in 2022 at "Surgical Neurology International"
DOI: 10.25259/sni_103_2022
Abstract: Background: The aim of this study was to identify prognostic factors associated with resection of intracranial metastases. Methods: A retrospective case series including patients who underwent resection of cranial metastases from March 2014 to April… read more here.
Keywords: prognostic factors; intracranial metastases; resection intracranial; overall survival ... See more keywords
The First Survival Score for Patients Treated with Whole-Brain Radiotherapy Plus Simultaneous Integrated Boost for Brain Metastases
Sign Up to like & getrecommendations! Published in 2023 at "Biology"
DOI: 10.3390/biology12040585
Abstract: Simple Summary A model was generated to judge survival after whole-brain radiotherapy plus simultaneous boost (WBRT+SIB) for cerebral metastases. Initially, three models, each including three prognostic groups, were created and compared for accuracy in prognosticating… read more here.
Keywords: brain radiotherapy; whole brain; brain; death ... See more keywords